# Filing Detail

Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-108869
Filing Date
2025-08-14
Accepted
2025-08-14 16:10:50
Documents
62
Period of Report
2025-06-30

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 10-Q | annx-20250630.htm iXBRL | 10-Q | 2786058
2 | EX-10.1 | annx-ex10_1.htm | EX-10.1 | 32294
3 | EX-31.1 | annx-ex31_1.htm | EX-31.1 | 17809
4 | EX-31.2 | annx-ex31_2.htm | EX-31.2 | 17220
5 | EX-32.1 | annx-ex32_1.htm | EX-32.1 | 15893
| Complete submission text file | 0000950170-25-108869.txt |  | 9092701

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
6 | XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT | annx-20250630.xsd | EX-101.SCH | 1043949
64 | EXTRACTED XBRL INSTANCE DOCUMENT | annx-20250630_htm.xml | XML | 1590018

Mailing Address 1400 SIERRA POINT PARKWAY BLDG C, SUITE 200 BRISBANE CA 94005
Business Address 1400 SIERRA POINT PARKWAY BLDG C, SUITE 200 BRISBANE CA 94005 (650)-822-5500
Annexon, Inc. (Filer) CIK: 0001528115 (see all company filings)

EIN.: 275414423 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39402 | Film No.: 251219086
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)